Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma

Authors: Pazdur R.1; Medgyesy D.C.1; Winn R.J.1; Dakhil S.R.2; Moore Jr. D.F.2; Scalzo A.3; Hoff P.M.1; Arbuck S.G.4; Abbruzzese J.L.1

Source: Investigational New Drugs, Volume 16, Number 4, 1998 , pp. 341-346(6)

Publisher: Springer

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

9-Aminocamptothecin (9-AC) is a camptothecin derivative with broad antitumor activity in preclinical studies. Prior investigations suggested that prolonged maintenance of 9-AC lactone plasma concentrations above 10 nmol/l and frequent administration of the drug are important determinants of antitumor activity. Our phase II study, therefore, examined a 5-day continuous infusion of 9-AC weekly for 3 weeks in patients with advanced colorectal cancer. Eighteen patients previously untreated for metastatic disease received 480 mgrg/m^2/day of 9-AC. No responses were observed in 17 evaluable patients. Severe toxicities included granulocytopenia, nausea, vomiting and diarrhea. The median absolute granulocyte count (AGC) nadir was 2,300/mgrl (range 0–9,000/mgrl) and occurred on day 10. Eight patients received an escalated dose of 600 mgrg/m^2/day. The median AGC nadir at the escalated dose was 1,500/mgrl (range: 300–2,700/mgrl) and occurred on day 22. The median number of courses given was 2 (range: 1–8); and the median time to disease progression was 8 weeks (range: 1–40 weeks). 9-AC administered by this schedule lacked antitumor activity in patients with advanced colorectal carcinomas.

Keywords: 9-AC; 9-aminocamptothecin; camptothecin; colorectal cancer; phase II

Language: English

Document Type: Regular paper

Affiliations: 1: Division of Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 2: Wichita CCOP, Wichita, KS 3: Syracuse CCOP, Syracuse, NY 4: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$42.00 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A